News

Somantix B.V.

SomantiX B.V. is a Dutch biotech company focusing on the identification and development of new angiogenesis inhibitors for the treatment of solid cancers through targeting of tumor blood vessels.
Somantix’ screening platform in combination with the binder generation technologies allows validation of new therapeutic targets and development of new cancer medicines.   

 

Contact

SomantiX B.V.

Padualaan 8

Hugo R. Kruyt building

Floor 8, Room O.807

3584 CH Utrecht
The Netherlands

Phone +31 (0)30-7600976

Email: info@somantix.com